Selected for FY 2024 “Drug Discovery Venture Ecosystem Enhancement Project”

We are pleased to announce that we have been selected by the Japan Agency for Medical Research and Development (AMED) as an implementing agency for the “Drug Discovery Venture Ecosystem Enhancement Project (Open Call for Drug Discovery Startups)” (4th round) for fiscal year 2024.
We will take this opportunity to further accelerate our business.

Takakura Lab has published the paper in terms of endothelial stem cells 

Takakura Lab has published the paper in terms of endothelial stem cells
（Matsui et al. Communications Biology 7, Article number: 338 (2024) .
They found that vascular regeneration by endothelial stem cell transplantation improved the dementia in mice.

Selected for the “KIDOU” project

We have been selected for “kidou”, a project to create global startups from Kansai.
We will further accelerate our business with support from “Kidou” for the next six months.

Selected for the ”NIPPON INNOVATION TRYOUT”

We have been selected for the ‘NIPPON INNOVATION TRYOUT’ for the 2024 UPDATE EARTH competition.
With the support over the next year, we aim for further business expansion with a global perspective.

Fundraising

Revascular Bio has received an investment of 220 million JPY from Osaka University Venture Capital Co., Ltd. Based on the funds raised this time, we will establish a method for preparing vascular endothelial stem cells and transfer the technology to a cell culture processing facility to realize cell therapy for intractable skin ulcers.

Selected for the UC Berkeley SkyDeck Accelerator Program.

Our President and CEO, Kazuo Omori, has been chosen to participate in the Berkeley Skydeck, a globally recognized startup accelerator program affiliated with the University of California, Berkeley. We are proud to announce our selection as a presenter for the final pitch competition.

Through this program, we aspire to expedite the development of our network and the expansion of our business in both the U.S. and global markets.